Kratom adverse effects include nausea, constipation, dizziness, and drowsiness. Rare but serious neurological, cardiovascular, breathing, and liver problems have also been reported. Understanding these reports means separating symptoms people describe, findings from laboratory research, and conclusions established in humans. Product differences and other substance exposure make that distinction especially important.
A new symptom after kratom use deserves attention without assuming that kratom explains everything. Adverse effects during exposure differ from kratom dependence and problematic use and from withdrawal concerns after stopping kratom. These issues can overlap, but they call for different explanations. The National Institute on Drug Abuse (NIDA) describes both reported harms and major gaps in knowledge. Its account supports taking symptoms seriously while avoiding claims that every product has the same effects, that every reported illness was caused by kratom alone, or that an uneventful experience proves future safety.
Written by Tim Francis, SUD Content Specialist. Tim is a nonclinical author. This guide supports discussion with qualified professionals.
What are kratom adverse effects, and why can experiences vary?
Kratom adverse effects are unwanted physical or mental changes reported after exposure to kratom products. They vary because products, other substances, health conditions, and prior exposure differ. These effects are a separate issue from kratom dependence or symptoms after stopping kratom, although those concerns can overlap.
Kratom refers to the tree Mitragyna speciosa and products derived from its leaves. Those leaves contain multiple biologically active compounds called alkaloids. Mitragynine and 7-hydroxymitragynine, also called 7-OH, are the best studied. A product's effects reflect more than its name or plant origin. According to NIDA's kratom research overview, the concentration and combination of compounds can influence its effects.
People report both stimulant-like effects, such as increased alertness and rapid heart rate, and opioid- or sedative-like effects, including relaxation and confusion. Those descriptions identify different experiences. They do not establish a dependable way to predict an individual's response.
NIDA identifies several reasons experiences may differ:
- The amount taken and the product's potency.
- The product's formulation and how it enters the body.
- Other drugs or medicines in the person's system.
- Underlying medical conditions.
- Previous experience with the substance.
People sometimes describe smaller amounts as stimulating and larger amounts as sedating. NIDA cautions that studies have not established that these effects depend on the amount or method consumed. That distinction rules out treating a familiar online description as a reliable exposure chart.
The term adverse effect also needs care. A symptom occurring after exposure establishes a sequence, but that sequence alone does not prove its cause. Researchers consider the substance, the product, other exposures, and alternative explanations. This uncertainty does not make the symptom unimportant. It means the explanation should remain proportional to the evidence rather than becoming an unsupported diagnosis.
Which kratom adverse effects are commonly reported?
Nausea, constipation, dizziness, and drowsiness are among the milder kratom adverse effects people report. These symptoms do not, by themselves, establish addiction or explain their own cause. Patterns of problematic kratom use and kratom withdrawal concerns are related but distinct subjects requiring attention to the circumstances.
NIDA lists these reported effects without providing a dependable percentage for each across all people and products. Calling them commonly reported symptoms should not be read as a measured prediction that a particular person will experience them.
- Nausea: feeling sick to the stomach.
- Constipation: difficulty passing stool.
- Dizziness: feeling unsteady or lightheaded.
- Drowsiness: feeling unusually sleepy or less alert.
These descriptions help name an experience, but they are not a self-diagnosis tool. Nausea can occur in many illnesses and after many exposures. The same applies to dizziness and sleepiness. A symptom's timing may provide useful context, yet timing cannot identify its cause with certainty.
The word mild describes how some effects have been reported. It does not mean every episode of that symptom is mild. NIDA also includes nausea and vomiting among gastrointestinal problems described in serious adverse-event reports. The symptom name alone therefore cannot determine the seriousness of the situation.
Likewise, ordinary sleepiness and being unable to wake someone are not interchangeable descriptions. A broad list of side effects should never be used to dismiss a major change in responsiveness as expected. Persistent, worsening, or otherwise concerning symptoms warrant medical assessment rather than an assumption that they must pass.
Impairment deserves its own distinction. NIDA says kratom's effects on driving and other safety-sensitive tasks have not been extensively studied. That research gap does not establish that an alert-feeling person is unimpaired, and the evidence does not provide a reliable waiting interval for driving. Dizziness, confusion, or drowsiness should not be treated as compatible with safe driving.
What rare but serious neurological, cardiovascular, and breathing problems have been reported with kratom?
Rare but serious reports associated with kratom exposure include confusion, tremors, seizures, high blood pressure, and slow breathing. These reports concern acute health effects, not simply kratom dependence. Exposure to several substances can complicate interpretation, and individual reports cannot establish how frequently these problems occur.
NIDA's summary of adverse-event evidence draws an important boundary: clinicians have described these problems in case reports, but research has not resolved every cause or risk factor. A case report records an actual clinical concern. It is not the same as a controlled study establishing that kratom alone caused the problem.
Neurological effects
Confusion, tremors, and seizures appear in the reported neurological effects. These are different findings, not steps in a predictable progression. Someone with nausea or dizziness is not thereby known to be progressing toward a seizure. Conversely, a serious neurological event should not be dismissed because other people describe only minor symptoms.
Cardiovascular effects
People report rapid heart rate among stimulant-like effects, and high blood pressure appears in serious clinical reports. Researchers also study possible cardiovascular toxicity in cells, animal models, and humans. A change observed in a laboratory model can identify a concern worth investigating, but it does not establish the frequency or severity of heart disease in people using varied products.
Breathing effects and laboratory findings
The breathing evidence requires particular precision. NIDA states that kratom leaves and mitragynine generally do not appear to produce the respiratory depression characteristic of a life-threatening opioid overdose. It also reports slow breathing in clinical cases associated with kratom exposure. Neither statement should be removed from its context.
In laboratory models, 7-OH can cause respiratory depression. The body converts mitragynine into 7-OH, but that conversion occurs slowly enough to limit mitragynine's breathing effects in the research NIDA describes. These findings concern particular compounds and experimental conditions. They do not establish that every product is equivalent or that breathing trouble after exposure is harmless.
NIDA also describes a small number of deaths linked to kratom products, with nearly all involving other drugs or contaminants. This complicates attribution. It does not justify declaring kratom harmless, assigning it sole responsibility in every case, or creating a personal safety ranking against other substances.
What is known and uncertain about kratom-associated liver problems?
Serious liver problems have been described in reports involving kratom, including regular, long-term use in large amounts. These reports do not establish a predictable threshold or explain every case. Concerns involving multiple substances and ongoing outpatient recovery support are relevant context, but neither replaces medical evaluation of possible liver injury.
NIDA describes the reported liver problems as appearing unpredictably in a small minority of people who use kratom. It also states that the roles of other substances and underlying health conditions remain unclear. Those qualifications are part of the finding, not reasons to ignore it.
The phrase associated with is useful here. It means liver problems and kratom exposure occurred together in the reported cases. Determining how much the kratom compounds, another ingredient, another substance, or an existing condition contributed is a separate task.
Long-term use appearing in reports does not establish that shorter exposure cannot cause harm. It also does not mean everyone with prolonged exposure has liver injury. The available evidence does not supply a universal safe duration, a safe amount, or a point at which injury becomes inevitable.
A person's symptoms cannot settle these questions alone. Feeling well does not constitute a liver assessment, while a new symptom does not establish that kratom has damaged the liver. Medical assessment addresses the actual health concern and possible explanations instead of working backward from a product name.
The evidence also does not support a promised recovery timetable or a claim that any possible injury will fully reverse. Such statements would require information about the person's condition and stronger evidence than an adverse-event summary provides.
For someone using kratom to manage pain, emotional distress, or another substance-related concern, possible liver problems and the original reason for use are separate care needs. Evaluating a medical concern need not mean abandoning discussion of the problem the person was trying to manage.
How can other substances and contaminants complicate kratom adverse-effect reports?
Other drugs, medicines, and contaminants can change the exposure being evaluated in a kratom adverse-effect report. Polysubstance-use concerns therefore differ from assuming a single cause. They also differ from kratom-related addiction concerns: a serious interaction or contaminated-product exposure does not itself establish a substance use disorder.
According to NIDA's evidence summary, many people who use kratom also use other drugs or have conditions for which medicines are prescribed. Case reports associate combinations involving kratom with severe outcomes, including liver problems and death. More research is needed to understand these combinations.
Several explanations may need consideration. Kratom compounds could contribute to an effect. Another substance could contribute. The combination could behave differently from either exposure alone. An underlying illness may also matter. A report involving several exposures cannot automatically resolve their separate contributions.
This is why an incomplete interaction list cannot function as a list of approved combinations. The absence of a well-documented interaction is not proof that combining two substances is safe. Current evidence does not provide a general rule that spacing exposures apart removes the concern.
Product contamination creates a different problem. NIDA reports that some kratom products have contained heavy metals or harmful bacteria. Those contaminants can produce effects that are not attributable to kratom compounds alone. Finding contamination in some products does not establish that every product is contaminated, but it prevents assuming that a product label fully describes the exposure.
Composition and contamination are also distinct. Two products can differ in their kratom compounds even without a contaminant. Conversely, an unwanted ingredient can add another health concern regardless of the intended alkaloid composition.
For interpreting an adverse event, the practical point is that “kratom exposure” may describe more than one substance or chemical mixture. Product details and other exposures provide clinical context. They do not make a symptom less real, and their relevance is not a judgment about the person seeking care.
What can current research establish about long-term kratom health risks?
Current research identifies reported harms and biological mechanisms, but it cannot reliably predict an individual's long-term outcome. Important gaps remain around repeated exposure, product differences, and coexisting conditions. Research on kratom dependence and withdrawal after regular use addresses additional questions rather than proving or disproving long-term organ safety.
NIDA states that long-term health effects are not well understood. Research is relatively new compared with research on more widely used drugs. Different forms of evidence answer different questions, so treating all findings as equivalent can create false certainty.
| Evidence type | What it can contribute | What it cannot establish alone |
|---|---|---|
| Self-reported experiences | Describe symptoms, perceived effects, and reasons for use. | Prove the cause of symptoms or predict every user's response. |
| Clinical case reports | Document serious events and identify concerns needing investigation. | Calculate how often an event occurs among all users. |
| Cell and animal research | Examine mechanisms and potential effects of particular compounds. | Directly establish human outcomes across different products. |
| Current long-term evidence | Identify reported concerns, including liver problems. | Define a universal safe duration or individual prognosis. |
A case report lacks the full denominator needed for a frequency estimate: the number of comparable people exposed, including those without the outcome. Even several reports cannot, by themselves, establish the percentage of users who will experience that event.
Laboratory research offers another kind of information. It can show how a compound acts on receptors or affects cells under defined conditions. That helps explain possible mechanisms. It does not mean the same outcome has been established in humans at every exposure.
Uncertainty also applies to pregnancy. NIDA reports very limited research and cases of opioid-like withdrawal in infants born to people who regularly used kratom. These reports warrant medical attention to pregnancy-related exposure, but they do not define the full range or frequency of possible outcomes.
Finally, possible therapeutic effects remain under investigation. People report using kratom for pain, mood symptoms, and opioid-related cravings or withdrawal. Those reasons for use do not establish treatment effectiveness. NIDA states that kratom has not been proven safe and effective for any medical purpose, and there are no FDA-approved medical uses. A research opportunity is not an established treatment recommendation.
How do medical assessment and ongoing recovery care address different kratom-related concerns?
Medical assessment addresses symptoms, possible toxicity, and other explanations for illness. Ongoing recovery care addresses substance-use patterns, coping, and daily functioning when those needs are present. Choice's Intensive Outpatient Program (IOP) is one outpatient pathway; contacting Choice concerns current services and fit, not emergency evaluation or a kratom-specific treatment promise.
A medical concern and a substance-use concern can exist together, but neither should be assumed from the other. Having nausea after exposure does not establish addiction. Having difficulty controlling use does not explain every new physical symptom. Keeping those questions separate allows both to receive appropriate attention.
Dependence and withdrawal deserve a brief distinction. NIDA reports that withdrawal symptoms can occur after regular kratom use, while the frequency and extent of related substance use disorder symptoms remain under study. It also states that no approved medical therapies specifically address these kratom-related conditions. Limited treatment reports do not establish a standard self-treatment regimen.
For substance use disorders generally, NIDA describes evidence-based treatment as addressing more than stopping a substance. Behavioral therapies can work on thoughts, motivation, stressful emotions, and cues connected with use. Co-occurring medical and mental health concerns may need care at the same time. These general principles do not establish a specific therapy or medication for kratom.
Choice's verified IOP description includes weekly group and individual therapy, learning about substance use disorder, and practicing recovery tools while living at home. Those services can support broader recovery needs. They do not replace medical evaluation of seizures, breathing problems, cardiovascular concerns, or possible liver injury.
Choice serves adults age 18 and older and provides outpatient services in Albuquerque, NM, and Las Cruces, NM. A routine conversation can clarify current outpatient options and the admissions process. It does not establish admission, a start date, or whether IOP is the appropriate level of care for a particular person.
Frequently asked questions about kratom adverse effects
Can kratom cause nausea, constipation, dizziness, or drowsiness?
Yes. NIDA lists nausea, constipation, dizziness, and drowsiness among reported kratom adverse effects. These reports do not provide a dependable percentage for every product or person. Symptoms also have other possible causes, so their appearance after kratom exposure is useful clinical context rather than proof of a diagnosis.
Have seizures or serious liver problems been reported with kratom exposure?
Yes. Clinical case reports have described seizures and serious liver problems associated with kratom exposure. NIDA characterizes serious effects as rare and notes uncertainty involving other substances and underlying conditions. These reports identify concerns that deserve attention, but they do not establish that kratom alone caused every event or predict an individual's risk.
Does a case report establish how often an adverse effect occurs?
No. A case report describes a clinical event, but it does not count all comparable people exposed, including those without symptoms. Without that denominator, it cannot establish the percentage who experience the effect. Case reports remain useful because they can identify serious concerns and direct further research.
Does an herbal origin establish that kratom is safe?
No. Plant origin does not establish safety, medical effectiveness, or consistent composition. Kratom contains biologically active compounds, products vary, and some products have contained contaminants. NIDA describes reported effects ranging from nausea and drowsiness to rare serious problems, while emphasizing that important short-term and long-term safety questions remain unresolved.
Is kratom a proven medical treatment for pain or opioid use disorder?
No. NIDA states that kratom has not been proven safe and effective for any medical purpose, and there are no FDA-approved medical uses. People report using it for pain or opioid-related symptoms, but self-reported benefit differs from established treatment evidence. Approved treatments for opioid use disorder are available through qualified medical care.
Sources
- National Institute on Drug Abuse: Kratom
- National Institute on Drug Abuse: Treatment
- Choice Recovery Path: Intensive Outpatient Program (IOP)
- Choice Recovery Path: Contact and adult outpatient access information
If ongoing substance use is something you want support with, you can review Choice's IOP or use the Choice contact page to discuss current outpatient options. You do not need to decide on a program before beginning that conversation.

